Scribe Therapeutics (SCTX) awards 14,725 stock options to director Bleharski

Rhea-AI Filing Summary

Scribe Therapeutics, Inc. director Joshua Bleharski received a grant of stock options for 14,725 shares of common stock on July 23, 2026. The options have an exercise price of $15.00 per share and expire on July 22, 2036. They vest in three equal annual installments on July 23 of 2027, 2028, and 2029, contingent on continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bleharski Joshua

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	14,725	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 14,725 shares (Direct)

Footnotes (1)

1. F1. The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Options Granted: 14,725 shares Exercise Price: $15.00 per share Expiration Date: July 22, 2036 +1 more

4 metrics

Options Granted 14,725 shares Stock options granted to director Joshua Bleharski on July 23, 2026

Exercise Price $15.00 per share Conversion or exercise price of the granted stock options

Expiration Date July 22, 2036 Expiration of the granted stock options

Underlying Shares 14,725 shares Common stock underlying the granted options

Key Terms

Stock Option (Right to Buy), exercise price, vesting

3 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 15.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The options will vest as to 1/3 of the total shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What did Scribe Therapeutics (SCTX) director Joshua Bleharski receive in this Form 4?

Director Joshua Bleharski received a stock option grant covering 14,725 shares of Scribe Therapeutics common stock at an exercise price of $15.00 per share, expiring on July 22, 2036.

What is the exercise price and term of the new SCTX stock options?

The granted options have an exercise price of $15.00 per share and an expiration date of July 22, 2036, giving the holder roughly a ten-year period to potentially exercise after vesting conditions are met.

How do the new Scribe Therapeutics (SCTX) options vest for Joshua Bleharski?

The options vest in three equal tranches of 1/3 each on July 23, 2027, July 23, 2028, and July 23, 2029, provided Joshua Bleharski continues to provide service to Scribe Therapeutics on each vesting date.

How many SCTX options does Joshua Bleharski hold after this transaction?

Following this grant, Joshua Bleharski holds 14,725 stock options relating to Scribe Therapeutics common stock as reported, all associated with this single award at a $15.00 exercise price.

Is the SCTX option grant to Joshua Bleharski a market purchase or a compensation award?

The transaction is classified as a grant or award acquisition of stock options, with no purchase price paid for the options themselves and an exercise price of $15.00 per share for future potential exercises.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 03:59 PM Accepted by SEC EDGAR 07/27/2026 - 09:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bleharski Joshua

(Last) (First) (Middle)

C/O SCRIBE THERAPEUTICS INC.

1150 MARINA VILLAGE PARKWAY

(Street)

ALAMEDA CALIFORNIA 94501

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Scribe Therapeutics, Inc. [ SCTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15	07/23/2026		A		14,725		(1)	07/22/2036	Common Stock	14,725	$0	14,725	D

Explanation of Responses:

1. The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ David L. Parrot, Attorney-in-Fact	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)